In a nutshell This study wanted to find out if adding targeted therapies to chemotherapy before surgery improved outcomes in patients with breast cancer. The study found that patients responded to treatment better when a targeted therapy was added to chemotherapy and surgery treatment. Some background There are multiple ways to treat breast...
Read More
In a nutshell This study aimed to investigate the effectiveness and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer. This study concluded that this combination was found to be safe and promising in these patients. Some background Pembrolizumab (Keytruda) is a targeted...
Read More
In a nutshell This study aimed to compare the safety and effectiveness of palbociclib and endocrine therapy to capecitabine chemotherapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. This study concluded that palbociclib and endocrine therapy is more effective than...
Read More
By Steve Gillman What my cancer taught me about medical “evidence” and how much is enough I exaggerate. My oncologist probably does believe humans need food, but I suspect the belief makes him uncomfortable, since no double-blind studies have been done to prove it. Like many doctors, his general approach to treatment is that if something hasn’t been...
Read MoreIn a nutshell This study aimed to investigate if fertility preservation in patients with invasive breast cancer would affect disease-free survival. This study concluded that fertility preservation appears unlikely to affect disease-free survival in these patients. Some background Fertility preservation (FP) is the process of saving or...
Read More
In a nutshell This study wanted to find out which treatment resulted in better overall survival for patients with HER2+ breast cancer; trastuzumab emtansine (Kadcycla) with or without pertuzumab (Perjeta), or trastuzumab (Herceptin) plus a taxane. The study found that the overall survival was similar across...
Read More
In a nutshell This trial is examining the safety and effectiveness of experimental drug mRNA-2752 in patients with advanced triple-negative breast cancer. The main outcome of the trial will be the number of side effects experienced by patients and response to treatment. This trial is recruiting in the United States and Israel. The details...
Read MoreIn a nutshell This study aimed to compare the outcomes for patients with early breast cancer who received 6- or 12-months trastuzumab after surgery. This study concluded that the standard duration of trastuzumab after surgery should remain 12 months. Some background Trastuzumab (Herceptin) is a targeted...
Read MoreIn a nutshell This trial aims to find out what dose of radiation therapy is effective in the shortest time period for women with newly diagnosed breast cancer, or ductal carcinoma in-situ (DCIS). The main outcome that will be measured is if patients experience any side effects. The study is taking place in New Jersey and New York, the United States. The...
Read MoreIn a nutshell This study is looking for postmenopausal patients with advanced breast cancer with an ESR1 mutation to compare lasofoxifene (Fablyn) to fulvestrant (Faslodex). The main outcome measured in this trial will be the patient’s survival without tumor growth or spread. This trial is recruiting in multiple locations in the United...
Read MoreIn a nutshell This study compared hormone therapy and chemotherapy for the treatment of metastatic (cancer that has spread) breast cancer. The authors concluded that hormone therapy plus targeted therapy is better than chemotherapy for patients with metastatic breast cancer. Some background Different types of breast cancer have different receptors....
Read More
In a nutshell This study aimed to investigate the effect of stopping trastuzumab treatment in patients with HER2-positive metastatic breast cancer with radiological complete remission. This study concluded that trastuzumab may be safely stopped in selected patients with radiological complete...
Read More
